Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Patients With Multiple Sclerosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-04-30

Study Completion Date

2017-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is an open-label, phase I clinical trial designed to evaluate the safety and tolerability of intrathecal administration of autologous mesenchymal stem cell-derived neural progenitor cells (MSC-NP) in patients with progressive multiple sclerosis. Study participants will receive three intrathecal injections of culture-expanded autologous MSC-NPs at three month intervals.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis

NCT03355365

Multiple Sclerosis

COMPLETED PHASE2

Expanded Access to Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis

NCT03822858

Multiple Sclerosis

AVAILABLE

Mesenchymal Stem Cells for Multiple Sclerosis

NCT01730547

Multiple Sclerosis

COMPLETED PHASE1/PHASE2

Mesenchymal Cells From Autologous Bone Marrow, Administered Intravenously in Patients Diagnosed With Multiple Sclerosis

NCT01745783

Multiple Sclerosis

COMPLETED PHASE1/PHASE2

Multi-Center Study Safety of Adipose Derived Mesenchymal Stem Cells for the Treatment of Multiple Sclerosis

NCT02326935

Multiple Sclerosis

TERMINATED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Sclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

autologous MSC-NP

intrathecal administration of autologous MSC-NP in three doses at three month intervals

Group Type EXPERIMENTAL

intrathecal administration of autologous MSC-NP

Intervention Type BIOLOGICAL

Autologous MSC-NPs administered intrathecally at a dose between 2 and 10 million cells, depending on ex vivo expansion characteristics. Three doses will be administered at 3 month intervals.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

intrathecal administration of autologous MSC-NP

Autologous MSC-NPs administered intrathecally at a dose between 2 and 10 million cells, depending on ex vivo expansion characteristics. Three doses will be administered at 3 month intervals.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of MS as defined by the McDonald criteria
* Diagnosis of primary progressive or secondary progressive MS
* Between the ages of 18-70 years
* Significant disability shown by an Expanded Disability Status Score (EDSS) of 3.0 or greater that was not acquired within the last 12 months
* Stable disease state as evidenced by a lack of gadolinium-enhancing lesions on an MRI and by a stable MRI disease burden (number of T2 lesions and size of lesions) in the last six months and no significant change in EDSS (1 point or more) in the last 12 months
* Must agree to undergo MRIs at the time of enrollment, 2 months after the first treatment, and 27 months after the last treatment
* Live in northern New Jersey, southern New York, or southwestern Connecticut during the study period, or patients must be able to arrange reliable travel accommodations to be present for every study visit if they live farther away.

Exclusion Criteria

* Pregnant or nursing mothers or any woman intending to become pregnant in the next three years
* All patients will have pre-study liver function tests, PT/PPT, platelets, hematocrit, and renal function laboratory tests done. Only patients whose values are in the normal range as determined by the laboratory norms based on age and sex will be allowed to participate.
* Use of systemic chemotherapeutic or anti-mitotic medications within three months of study start date due to the possibility of interference with bone marrow procedure
* Any patients with a history of or with active malignancy
* Use of steroids within three months of the study start date, as this would suggest a highly active disease state
* History of cirrhosis due to increased risk of central nervous system (CNS) infection
* Poorly controlled hypertension because of increased risk for stroke or CNS hemorrhage. Specifically, any patient with a systolic blood pressure value of ≥ 145 mm/Hg or a diastolic blood pressure value of ≥ 95 mm/Hg will be excluded from study participation.
* History of thyroid disorders or other endocrine disorders because of hormone influence on cell growth
* History of central nervous system infection or immunodeficiency syndromes due to increased risk of CNS infection
* Preexisting blood disease (such as bone marrow hypoplasia, leukopenia, thrombocytopenia, or significant anemia) due to invasive nature of bone-marrow aspiration
* Previous or current history of a coagulation disorder
* Any metal in the body, which is contraindicated for MRI studies
* Allergy to any of the antibiotics used in this study, e.g. tobramycin, vancomycin, or gentamicin
* Patients with alcohol or other substance abuse problems
* Other major disease that, in the opinion of the Principal Investigator, would preclude participation in the study
* Patients with HBV, HCV, syphilis, HIV-1, or HIV-2.
* Any evidence of significant cognitive dysfunction based on a screening history and physical examination because it would preclude giving a truly informed consent
* Patients who are enrolled in another clinical trial for MS treatment or who have received any study drug/biologics within the last 6 months

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No